Acadia Healthcare Company, Inc.

DB:7RA Stock Report

Market Cap: €4.0b

Acadia Healthcare Company Valuation

Is 7RA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7RA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7RA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7RA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7RA?

Key metric: As 7RA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 7RA. This is calculated by dividing 7RA's market cap by their current earnings.
What is 7RA's PE Ratio?
PE Ratio14.5x
EarningsUS$280.73m
Market CapUS$4.07b

Price to Earnings Ratio vs Peers

How does 7RA's PE Ratio compare to its peers?

The above table shows the PE ratio for 7RA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.6x
RHK RHÖN-KLINIKUM
21.8x7.5%€977.3m
M12 M1 Kliniken
17.5x16.0%€293.2m
LIK LIMES Schlosskliniken
23.3xn/a€99.7m
SYAB SYNLAB
27.7x-11.4%€2.5b
7RA Acadia Healthcare Company
14.5x10.1%€4.1b

Price-To-Earnings vs Peers: 7RA is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does 7RA's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
7RA 14.5xIndustry Avg. 19.7xNo. of Companies8PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 7RA is good value based on its Price-To-Earnings Ratio (14.5x) compared to the European Healthcare industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is 7RA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7RA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.5x
Fair PE Ratio30.3x

Price-To-Earnings vs Fair Ratio: 7RA is good value based on its Price-To-Earnings Ratio (14.5x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7RA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€40.60
€59.62
+46.8%
18.2%€75.75€41.76n/a13
Jan ’26€36.20
€58.54
+61.7%
18.7%€75.26€41.49n/a12
Dec ’25€38.20
€57.78
+51.3%
18.7%€76.82€41.29n/a12
Nov ’25€39.00
€63.67
+63.3%
20.8%€86.74€41.53n/a12
Oct ’25€56.50
€79.48
+40.7%
10.1%€94.04€67.17n/a12
Sep ’25€72.50
€81.86
+12.9%
9.3%€96.21€68.72n/a12
Aug ’25€59.50
€81.86
+37.6%
11.4%€97.30€64.87n/a12
Jul ’25€62.50
€82.62
+32.2%
11.3%€97.84€65.23n/a12
Jun ’25€62.00
€81.68
+31.7%
11.3%€96.73€64.48n/a12
May ’25€69.50
€88.45
+27.3%
9.8%€96.89€64.60n/a13
Apr ’25€72.00
€87.72
+21.8%
10.1%€96.36€64.24n/a12
Mar ’25€77.00
€87.47
+13.6%
11.5%€97.15€64.76n/a11
Feb ’25€76.00
€81.84
+7.7%
11.1%€95.97€62.15n/a11
Jan ’25€70.50
€80.97
+14.8%
11.5%€96.01€62.18€36.2011
Dec ’24€66.50
€82.59
+24.2%
11.5%€97.93€63.42€38.2011
Nov ’24€69.00
€84.86
+23.0%
11.7%€98.90€64.05€39.0011
Oct ’24€66.50
€84.74
+27.4%
11.3%€98.27€63.64€56.5011
Sep ’24€71.00
€82.95
+16.8%
11.0%€95.97€62.15€72.5012
Aug ’24€71.50
€82.38
+15.2%
11.0%€95.49€61.84€59.5012
Jul ’24€73.00
€81.45
+11.6%
12.0%€95.29€57.17€62.5012
Jun ’24€66.00
€81.45
+23.4%
12.0%€95.29€57.17€62.0012
May ’24€66.00
€81.45
+23.4%
12.0%€95.29€57.17€69.5012
Apr ’24€65.00
€86.40
+32.9%
8.8%€98.34€70.25€72.0012
Mar ’24€68.50
€87.62
+27.9%
6.7%€98.48€76.91€77.0012
Feb ’24€77.00
€89.96
+16.8%
6.7%€99.78€77.92€76.0012
Jan ’24€77.00
€89.55
+16.3%
7.0%€99.68€77.84€70.5012
Analyst Price Target
Consensus Narrative from 13 Analysts
€56.93
Fair Value
28.7% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 02:52
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acadia Healthcare Company, Inc. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew GillmorBaird
Ishan MajumdarBaptista Research
Sarah JamesBarclays